Clinical trial
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the…
NCT00449033 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00449033 |
|---|---|
| Title | A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) |
| Acronym | NEXUS |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Placebo, Gemcitabine, Cisplatin |
| Enrollment | 904 |
| Start date | Feb 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Mar 19, 2007 |
| Last update posted | Apr 23, 2015 |
| Countries | Austria, Belgium, Brazil, Canada, China, Cyprus, Finland, France, Germany, Greece, Hungary, Israel and 6 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: